Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1247460.RA9_PMFF03FLWlt9WyovbAVOh-bJ6-y9bpmwnid6llqiY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1247460.RA9_PMFF03FLWlt9WyovbAVOh-bJ6-y9bpmwnid6llqiY130_assertion type Assertion NP1247460.RA9_PMFF03FLWlt9WyovbAVOh-bJ6-y9bpmwnid6llqiY130_head.
- NP1247460.RA9_PMFF03FLWlt9WyovbAVOh-bJ6-y9bpmwnid6llqiY130_assertion description "[Dasatinib is a BCR-ABL kinase inhibitor with improved potency compared with imatinib, for which efficacy and safety in imatinib-resistant and imatinib-intolerant patients with chronic myelogenous leukemia (CML) have been established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1247460.RA9_PMFF03FLWlt9WyovbAVOh-bJ6-y9bpmwnid6llqiY130_provenance.
- NP1247460.RA9_PMFF03FLWlt9WyovbAVOh-bJ6-y9bpmwnid6llqiY130_assertion evidence source_evidence_literature NP1247460.RA9_PMFF03FLWlt9WyovbAVOh-bJ6-y9bpmwnid6llqiY130_provenance.
- NP1247460.RA9_PMFF03FLWlt9WyovbAVOh-bJ6-y9bpmwnid6llqiY130_assertion SIO_000772 25501110 NP1247460.RA9_PMFF03FLWlt9WyovbAVOh-bJ6-y9bpmwnid6llqiY130_provenance.
- NP1247460.RA9_PMFF03FLWlt9WyovbAVOh-bJ6-y9bpmwnid6llqiY130_assertion wasDerivedFrom befree-2016 NP1247460.RA9_PMFF03FLWlt9WyovbAVOh-bJ6-y9bpmwnid6llqiY130_provenance.
- NP1247460.RA9_PMFF03FLWlt9WyovbAVOh-bJ6-y9bpmwnid6llqiY130_assertion wasGeneratedBy ECO_0000203 NP1247460.RA9_PMFF03FLWlt9WyovbAVOh-bJ6-y9bpmwnid6llqiY130_provenance.